Summit Therapeutics PLC (SMMT)

NASDAQ
1.020
-0.040(-3.77%)
  • Volume:
    20,407
  • Day's Range:
    1.020 - 1.030
  • 52 wk Range:
    1.010 - 8.700

SMMT Overview

Prev. Close
1.06
Day's Range
1.02-1.03
Revenue
1.87M
Open
1.02
52 wk Range
1.01-8.7
EPS
-0.97
Volume
20,407
Market Cap
103.03M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
110,683
P/E Ratio
-
Beta
1.03
1-Year Change
-84.53%
Shares Outstanding
98,122,356
Next Earnings Date
Aug 10, 2022
What is your sentiment on Summit Therapeutics PLC?
or
Vote to see community's results!

Summit Therapeutics PLC News

Summit Therapeutics PLC Analysis

Summit Therapeutics PLC Company Profile

Summit Therapeutics PLC Company Profile

Employees
108

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Summit on the way up!
    0
    • what happens here ? anybody ? somebody knows ? what is this rocket ?
      0
      • interesting progress they are making in the field of vaccines.. keep the good job.
        0
        • this will be a very interesting to look at when the market opens.
          0